Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLENDOUR: Denosumab + Chemotherapy in Advanced NSCLC
NCT02129699Phase 3Terminated
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Jan 2015
- Primary completion
- Feb 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of denosumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Overall Survival at 56 months. Started Jan 2015; status: terminated.
02
Drugs
denosumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02129699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02129699.